By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian life science firm SQI Diagnostics has filed a preliminary prospectus to raise up to $30 million in an initial public offering in the US.

In a Form F-10 filed with the US Securities and Exchange Commission on Wednesday, the firm, which trades on the Toronto Stock Exchange, said that is has been approved for listing on NYSE Amex under ticker symbol "SQD."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.